Not medical advice. A record of published research and our assessments of it. The limits

GLP-1 receptor agonists increase suicidal ideation or suicide.

Current status: Not supportedEvidence weakening · Psychiatric
Why: Pharmacovigilance reports prompted regulatory review. Two large cohorts (US EHR; Swedish/Danish registers with SGLT2i active comparator) found no increase in suicidal ideation or suicide death; the Nordic upper confidence limit excludes more than 0.16 extra deaths per 1,000 person-years.
What would change it: A signal in randomized psychiatric adverse-event data or in people with pre-existing psychiatric illness.
Linked studies: 2 · 2 contradicts
Last updated: Sep 13, 2026

The status is the collection's own judgment on its assessment scale, not a GRADE certainty rating and not medical advice.

01The evidence

The evidence, sorted by what it shows

Association of semaglutide with risk of suicidal ideation in a real-world cohortRetrospective cohort · 2024 · Study tier 3 · Different population · Null
TriNetX observational EHR cohort in overweight or obesity, replicated in type 2 diabetes: semaglutide had lower 6-month risk of incident (HR 0.27) and recurrent (HR 0.44) suicidal ideation than non-GLP-1 anti-obesity drugs; suicide death was not studied.
GLP-1 Receptor Agonist Use and Risk of Suicide DeathRetrospective cohort · 2024 · Study tier 3 · Different population · Null
Swedish and Danish register cohort, mostly type 2 diabetes, versus SGLT2 inhibitors: suicide death HR 1.25 (95% CI 0.83-1.88), not significant, with an absolute increase of at most 0.16 per 1000 person-years; suicide death or nonfatal self-harm HR 0.83 (0.70-0.97); incident depression and anxiety HR 1.01 (0.97-1.06). Observational; suicidal ideation not measured.

02History